J.P. Morgan 40th Annual Healthcare
Conference
Curt R. Hartman
Chair of the Board, President, and Chief Executive Officer
Todd W. Garner
Executive Vice President and Chief Financial Officer
January 10, 2022
Forward-Looking Information
This presentation contains forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties. The forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company's performance on a going-forward basis. The forward-looking statements in this presentation involve risks and uncertainties which could cause actual results, performance or trends, to differ materially from those expressed in the forward-looking statements herein or in previous disclosures. For example, in addition to general industry and economic conditions, factors that could cause actual results to differ materially from those discussed in the forward-looking statements in this presentation include, but are not limited to, the risks posed to the Company's business, financial condition, and results of operations by the COVID-19global pandemic and the various government responses to the pandemic, including deferral of surgeries, reductions in hospital and ambulatory surgery center operating volumes, disruption to potential supply chain reliability, as well as the risk factors discussed in the Company's Annual Report on Form 10-Kfor the full year ended December 31, 2020 and listed under Forward Looking Statements in the Company's most recently filed Form 10-Q.
Management has disclosed adjusted financial measurements in this presentation that present financial information that is not in accordance with generally accepted accounting principles (GAAP). The Company analyzes net sales on a constant currency basis to better measure the comparability of results between periods. To measure earnings performance on a consistent and comparable basis, the Company excludes certain items that affect the comparability of operating results and the trend of earnings. These adjustments are irregular in timing, may not be indicative of past and future performance and are therefore excluded to allow investors to better understand underlying operating trends. These measurements are not a substitute for GAAP measurements. Investors should consider adjusted measures in addition to, and not as a substitute for, or superior to, financial performance measures prepared in accordance with GAAP.
2
CONMED Vision |
Empower healthcare providers worldwide to deliver |
exceptional outcomes for patients. |
Focus behind the Vision |
People, Products, Profitability |
3 |
Objectives for Our Shareholders |
▪ Aggregate growthand profitability over the long term to significantly |
increase the valuation of the company |
▪ Increase our market sharein large and attractive markets |
▪ Deliver above-marketrevenue and profitability growthover the long term |
4 |
Orthopedics: Large, Attractive Markets
Category | Description | Market Size and Competitors | Dollar Value of 1 Market Share Point | ||||
Sports | $4.4 to $4.6 Billion | ~$45M | |||||
Q3 2021 YTD | Devices for repair of soft | ▪ | Arthrex | ▪ | Stryker | ||
Medicine | tissue injuries in joints | ▪ | DePuy Mitek (J&J) | ||||
▪ | Smith & Nephew | ▪ | Zimmer Biomet | ||||
Allograft | Exclusive commercial | $375 to $425 Million | |||||
▪ | Allosource | ~$4M | |||||
rights to MTF allograft | |||||||
▪ | |||||||
Tissue | tissue | LifeNet | |||||
▪ | RTI | ||||||
US | Surgical drills and saws | $1.4 to $1.6 Billion | |||||
Powered | ▪ | ~$15M | |||||
36% | DePuy Synthes (J&J) | ||||||
with related single-use | ▪ | ||||||
Stryker | |||||||
International | Instruments | accessories | ▪ | Medtronic (Midas Rex / Xomed) | |||
▪ | Zimmer Biomet | ||||||
64% | |||||||
High-definition surgical | $1.8 to $2.0 Billion | ||||||
Surgical | ▪ | Stryker | |||||
visualization systems to | ▪ | Olympus | ~$19M | ||||
Visualization | enable minimally invasive | ▪ | Arthrex | ▪ | Richard Wolf | ||
▪ | Karl Storz | ▪ | |||||
Smith & Nephew | |||||||
71% | arthroscopic surgery | ||||||
~$83M | |||||||
Recurring, single-use revenue | |||||||
Total | 60% to 70% in Surgery Centers in the U.S. | ~8% growth for total | |||||
Orthopedics | company based on 2019 | ||||||
revenue | |||||||
5
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
CONMED Corporation published this content on 10 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 10 January 2022 17:47:10 UTC.